The regulatory approval means that the assay for minimal residual disease is available to monitor B cell blood cancers in patients in all 50 states.

The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.

Product and service revenues were up 10 percent year over year to $22.4 million compared to $20.4 million in the year-ago quarter.

The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.

Through a transcriptomic analysis, the researchers developed a catalog of gene expression with the olfactory mucosa of half a dozen mammals.

The partners will request samples from more than 2,500 existing and new participants in the foundation's Preeclampsia Registry for sequencing analysis.

The firm aims to stabilize and protect its existing molecular diagnostics business over the next 12 to 18 months, CEO Jack Kenny said.

With exome sequences for tens of thousands of Finns, researchers identified deleterious variants linked to dozens of clinically relevant quantitative traits.

The research team said its nanofluidic system increased the proportion of nucleic acid and protein disease biomarkers a billionfold prior to detection.

A Japanese researcher may soon be developing rat and mouse embryos with human cells as part of a plan to eventually develop organs for transplants, according to Nature News.

Three medical writing organizations warn about the harm predatory journals could do to the scientific literature.

Kentucky law enforcement officials are testing a rapid DNA analyzer in sexual assault cases, CNBC reports.

In Nucleic Acids Research this week: the hidden human proteome, single-cell-based expression signatures, and more.

The new company, whose name was not disclosed, will provide preclinical and clinical immune monitoring and biomarker services to biopharma companies.

The company also reported higher operating costs as it worked to develop and validate its Parsortix circulating tumor cell collection system for clinical use.

As MPEG LA tries to complete its larger CRISPR IP patent pool, smaller license agreements continue and a mini-pool has emerged between key players.

Blue Cross Blue Shield of Michigan's members will able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.

San Diego, California-based molecular diagnostics developer Mesa Biotech has launched a respiratory syncytial virus test on its sample-to-answer point-of-care PCR system, the Acula. The RSV test is the second test on the system, which also runs an influenza A/B test and is exclusively marketed in the US by Sekisui under the Silaris brand. It was cleared by the US Food and Drug Administration and CLIA-waived last year for diagnostic use in both children and adults.

QGel is looking to raise $60 million to begin clinical testing of its technology for pharmaceutical product development for targeted cancer therapy.

For the three months ended June 30, the genomic testing firm reported total revenues of $30.1 million.

Qiagen's Q2 revenues of $381.6 million represented 5 percent year-over-year growth at constant exchange rates, but came in just under the Wall Street estimate.

The partners are working under NIAAA grants to identify genetic markers to help predict response to the drug acamprosate, which is used as a treatment for alcoholism.

An international team documented TP53 mutation-related genomic changes across dozens of cancer types using data generated with five platforms for the Cancer Genome Atlas project.

During a conference call to discuss the firm's second-quarter results, CEO and President Francis deSouza also highlighted potential growth from clinical sequencing.

Researchers have sequenced and analyzed the genomes of two Komodo dragons, the International Business Times reports.